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Background: Grass pollens are significant elicitors of IgE-mediated allergic disease in the world and timothy
(Phleum pratense) is one of the most important pollens of the family. Molecular and biochemical characterization
of Phleum pratense has revealed several allergen components: rPhl p 1 and rPhl p 5 have been shown to be
“Species Specific Allergens”, while the profilin rPhl p 12 and the calcium-binding protein rPhl p 7 are the principal
Cross-Reactive components.
Methods: In this study the pattern of sensitization to rPhl p 1, rPhl p 5, rPhl p 7 and rPhl p 12 was analyzed in
children with asthma and/or rhinoconjunctivitis and grass pollen allergy, in order to evaluate the frequency of
sensitization to allergenic molecules of Phleum pratense among pediatric subjects allergic to grass pollen in a
Mediterranean population. The correlation of sensitization to these Phleum allergenic molecules with IgE against
grass pollen extract and its variation according to age and level of IgE against grass pollen extract were evaluated.
Results: IgE against to rPhl p 1 were found in 99% (205/207) of patients, to rPhl p 5 in 67% (139/207), to rPhl p 12
in 32% (66/207) and to rPhl p 7 only in 5% (10/207).
Sensitization only to “Species Specific” (rPhl p1, rPhl p5) allergenic molecules of Phleum pratense was detected in
65% (135/207) of children. Our data show the predominant role of rPhl p 1 in pediatric populations as the most
relevant sensitizing allergen detectable at all ages and at all levels of timothy grass pollen-specific IgE antibodies,
while the importance of rPhl p 5 rises with the increase of patients’ age and with grass pollen IgE levels.
Conclusions: The assessment of sensitization to grass pollen allergenic molecules could help develop a better
characterization of allergic sensitization in grass pollen allergy in children, which may be different in every patient.
It could also enable clinicians to give more specific and effective immunotherapy, based on allergenic molecule
sensitization.
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Traditional allergen extracts, used for diagnosis and ther-
apy, are prepared from natural allergen sources such as a
mixture of different grass species, and contain mixed aller-
genic components in undefined amounts of non allergenic
materials. These components are difficult to standardize
and in many cases important allergens are present in small
amounts or lacking, such as their biological potency is
subject to wide variability [1,2]. On the contrary, recom-
binant allergens can be produced with high purity by* Correspondence: ale.scaparrotta@libero.it
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distribution, and reproduction in any mediumusing controlled procedures that yield defined molecules
with known molecular, immunologic, and biological
characteristics [3,4].
In the late 1980s the rapid development of molecular
biological techniques allowed the cloning of the first
molecular allergen [5], and the subsequent advent of re-
combinant technology provided a large panel of allergenic
molecules [1,6-8].
Grass pollens are important causes of IgE-mediated
allergic disease in the world and approximately 40% of
allergic patients show IgE reactivity to these allergens
[9-11]. Timothy grass (Phleum pratense or Pp) is the mosttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 General, allergological and clinical characteristics
of the study population
Characteristics of population N° of patients (%)
Number of patients 207
Males 145
Females 62
Mean Age (years) 9.7 ± 3.6
Respiratory Allergy
Timothy Grass Pollen 207/207
Parietaria judaica 150/207 (72%)
Olea 176/207 (85%)
House dust mite 108/207 (52%)
Moulds 58/207(28%)










Urticaria, Angioedema, Anaphylaxis 24/207 (12%)
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central Europe [12,13].
Molecular and biochemical characterization of Pp [12]
has revealed several allergen components as rPhl p 1,
rPhl p 2, nPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11
and rPhl p 12, of which rPhl p 1 and rPhl p 5 have been
shown to be the “Species Specific Allergens” [14,15]; the
profilin rPhl p 12 [12,16] and the calcium-binding pro-
tein rPhl p 7 are the main Cross-Reactive components.
The major part of the studies conducted to assess the
utility of molecular diagnosis based on recombinant
allergens have been performed on a sample of popula-
tion with a very wide range of ages (from childhood to
adulthood); few epidemiological studies have been
performed exclusively in the pediatric age.
In this study, the pattern of sensitization to rPhl p 1,
rPhl p 5, rPhl p 7 and rPhl p 12 in children with asthma
and/or rhinoconjunctivitis and grass pollen allergy (posi-
tive IgE against timothy grass pollen extract) was analyzed,
in order to evaluate the frequency of sensitization to aller-
genic molecules of Pp in children with pollen allergy in a
Mediterranean population.
The correlation of sensitization to these Pp allergenic
molecules with IgE against grass pollen extract and its
variation according to different ages and different levels
of IgE against grass pollen extract were evaluated.
Methods
Study population
207 patients (62 females and 145 males), mean age 9.7 ±
3.6 years, referring to the Allergy and Respiratory Unit
of Pediatric Clinic, University Hospital, Chieti, Italy,
were recruited between August 2008 and April 2010.
The selection was based on a positive history of allergic
asthma and/or rhinoconjunctivitis and timothy grass
pollen (Pp) allergy, confirmed by allergological evaluation
(skin prick tests and Pp specific IgE positivity).
All patients were polysensitized to other respiratory
and food allergens, listed in Table 1.
The ethical committee of the University of Chieti
approved the study performed in accordance with Helsinki
Declaration (1964); written informed consent was obtained
from the parents of all patients.
Methods
Serum specific IgE against timothy grass pollen (Pp)
extract and serum specific IgE against Pp allergenic
molecules (rPhl p 1, expansin family; rPhl p 5, ribonucle-
ase family; rPhl p 7 polcalcin family; and rPhl p 12 profilin
family) were measured using ImmunoCAP (Phadia AB,
Uppsala, Sweden).
IgE against grass pollen extract and IgE against aller-
genic molecules of Pp were scored according to the RAST
rating: RAST rating 1 (0.35 - 0.69 kUA/l); RAST rating 2(0.70 - 3.49 kUA/l); RAST rating 3 (3.50 - 17.49 kUA/l);
RAST rating 4 (17.50 - 49.99 kUA/l); RAST rating 5 (50.0 -
100.00 kUA/l); RAST rating 6 (> 100 kUA/l). IgE were
considered positive at the level of 0.35 kUA/l (class I or
RAST rating 1) or higher.
Total IgE were considered high according to the
reference age-related value of ImmunoCAP Total IgE,
Phadia.
The correlation between IgE against Pp allergenic
molecules and IgE against timothy grass pollen (Pp)
extract was analyzed.
The frequency of patients with positive serum IgE
against Pp allergenic molecules was correlated with
serum IgE against grass pollen (Pp) extract (according to
RAST scores), in order to verify an IgE cut-off of
sensitization to rPhl p 1 and rPhl p 5 IgE.
The frequency of sensitization to Pp allergenic molecules
according to the age was also studied, dividing the patients
in three groups: age < 5 years; age between 5 to 10 years;
age > 10 years.
We also analyzed the sensitization to other allergens in
patients with positivity to “Species Specific” allergenic
molecules (rPhl p 1, rPhl p 5) and Cross-Reactive allergenic
molecules, comparing the pattern of polysensitization with
Figure 1 Pattern of sensitization to allergenic molecules of Pp
in 207 timothy grass pollen allergic children. Number and
percentage of patients with: a) sensitization to all allergenic
molecules; b) sensitization to “Species Specific” allergenic molecules
alone; c) sensitization to “Species specific” and Cross-Reactive
allergenic molecules.
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genic molecules.
Finally, possible correlations between clinical symptoms
(asthma, rhinitis, rhinoconjunctivitis, urticaria, anaphyl-
axis, angioedema) and sensitization to Pp allergenic
molecules were explored.
Statistical analysis
Results are expressed as Mean (M) ± Standard Deviation
(SD). Mean values are compared using unpaired T Test.
P values < 0.05 are considered statistically significant.
The Pearson correlation coefficient was used to find
correlations between allergological and laboratory
parameters. Differences between groups of patients have
been analyzed using the Chi square (χ2) Test and Yates’
corrected Chi square (Yates’ χ2) Test. SPSS Inc PASW
Statistics 18 was used for the statistical analysis.
Results
High total IgE levels in relation to the age were found in
91% (189/207) of patients.
The frequency of allergic symptoms in our patients is
listed in Table 1.
IgE against rPhl p 1 were found in 99% (205/207) of
patients, against rPhl p 5 in 67% (139/207), against rPhl
p 12 in 32% (66/207) and against rPhl p 7 only in 5%
(10/207) (Figure 1a).
Sensitization only to “Species Specific” allergenic
molecules of Pp was detected in 65% (135/207) of chil-
dren: in particular, sensitization only to rPhl p 1 was found
in 55/207 (26%) patients, only to rPhl p 5 in 2/207 (1%)
children and to rPhl p 1 + rPhl p 5 in 78/207 (38%)
patients (Figure 1b).
No children had positive IgE only against rPhl p 7 and
rPhl p 12.
Sensitization to “Species Specific” and Cross-Reactive al-
lergenic molecules of Pp was detected in 35% (72/207) of
patients: IgE against rPhl p 1 + rPhl p 5 + rPhl p 12 were
found in 25% of patients (52/207); against rPhl p 1 + rPhl
p 12 in 5% (10/207 ones); against rPhl p 1 + rPhl p 5 +
rPhl p 7, and against rPhl p 1 + rPhl p 7 in 1.5% (3/207
patients. Simultaneous positivity to all four allergenic
molecules was detected in a very small number of children
(rPhl p 1 + rPhl p 5 + rPhl p 7 + rPhl p 12 in 4/207; 2%)
(Figure 1c).
High significant correlations were observed between
IgE levels against timothy grass pollen extract and: rPhl
p 1 IgE (Pearson coefficient: 0.87, p = 0.01); rPhl p 5 IgE
(Pearson coefficient: 0.77, p = 0.01), whereas lower
correlations were found with rPhl p 7 IgE (Pearson coef-
ficient: 0.19, p = 0.01) and rPhl p 12 IgE (Pearson coeffi-
cient: 0.36, p = 0.01).
When we analyzed IgE levels against timothy grass
pollen extract and RAST rating we found that 24/207,37/207, 41/207, 43/207 and 62/207 patients had a RAST
rating of 2, 3, 4, 5 and 6, respectively.
rPhl p 1 IgE were detectable from 97% to 100% as
in patients with low grade of sensitization as in high
sensitized ones, regardless of the level of IgE against
timothy grass pollen extract (Figure 2). So, there were
no statistically significant differences in the positivity of
IgE for rPhl p 1 according to IgE against timothy grass
pollen extract levels.
rPhl p 5 IgE positivity raised with the increase of IgE
against timothy grass pollen extract (Figure 2), with
statistically significant differences (Table 2).
Monosensitization to rPhl p 1 was very important in
patients with lower IgE against timothy grass pollen
Figure 2 IgE positivity for Phleum “Species Specific” allergenic molecule according to grass pollen IgE levels in timothy grass pollen
allergic children. Abbreviation: pts = patients.
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against timothy grass pollen extract level (Figure 2), with
statistically significant differences (Table 2).
rPhl p 5 IgE positivity became the same as rPhl p 1 in
patients with IgE against timothy grass pollen extract
level ≥ 100 kUA/l (Figure 2).
rPhl p 12 IgE positivity raised with the increase in IgE
against timothy grass pollen extract, with statistically
significant differences (Table 2).
Figure 2 shows IgE positivity for rPhl p 1, rPhl p5 and
only rPhl 1 according to timothy grass pollen IgE levels
(Figure 2), while Table 2 summarizes the statistical
significance that emerges comparing the positivity for Pp
allergenic molecules IgE between groups of patients withTable 2 Comparison of the positivity for Phleum allergenic m
IgE values against timothy grass pollen extract levels
rPhl p 5 IgE O
GRASS POLLEN IgE GROUPS χ2 Yates’ χ2 p χ
RAST rating 2 vs 3 10.7 9 p < 0.01 1
RAST rating 2 vs 4 14.6 12.6 p < 0.01 2
RAST rating 2 vs 5 33.2 30.4 p < 0.01 4
RAST rating 2 vs 6 71.6 67.1 p < 0.01 7
RAST rating 3 vs 4 – – ns –
RAST rating 3 vs 5 9.5 8.1 p < 0.01 1
RAST rating 3 vs 6 35.6 32.5 p < 0.01 3
RAST rating 4 vs 5 6.3 5.2 p < 0.05 7
RAST rating 4 vs 6 29.3 26.6 p < 0.01 2
RAST rating 5 vs 6 9.3 7.3 p < 0.01 4different IgE against timothy grass pollen extract levels
(Table 2).
The patients aged < 5 years were 17/207 (8%), 12
males and 5 females, those aged between 5 to 10 years
were 102/207 (49%), 68 males and 34 females, and those
aged > 10 years 88/207 (43%), 65 males and 23 females.
Hereinafter we report the pattern of specific IgE to rPhl
p 1, rPhl p 5, rPhl p 7 and rPhl p 12 in children divided
in three groups according to the age (the first group < 5
years, the second group between 5 and 10 years, and the
third group > 10 years): rPhl p 1 in 100% (17/17), 99%
(101/102) and 99% (87/88) in the 1st, 2nd, and 3rd group,
respectively; rPhl p 5 in 59% (10/17), 67% (68/102) and
69% (61/88), respectively; rPhl p 7 in 0%, 6% (6/102) andolecules IgE between groups of patients with different
nly rPhl p 1 IgE rPhl p 12 IgE
2 Yates’ χ2 p χ2 Yates’ χ2 p
1.9 10.1 p < 0.01 – – ns
3.6 21.2 p < 0.01 8.6 6.8 p < 0.01
7.2 43.7 p < 0.01 11.7 9.8 p < 0.01
6.4 71.6 p < 0.01 25.1 22.8 p < 0.01
– ns 9.9 8.1 p < 0.01
7.8 15.7 p < 0.01 14.1 12.2 p < 0.01
6.9 33.7 p < 0.01 31.8 29.4 p < 0.01
.11 5.7 p < 0.01 – – ns
p < 0.05
0.5 17.8 p < 0.01 9.1 8 p < 0.01
.4 p < 0.05 5.1 4.3 p < 0.05
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36% (32/88); and finally mononosensitization only to
rPhl p 1 was detected in 35% (6/17), 28% (29/102) and
23% (20/88), while only to rPhl p 5 in 0%, 1% (1/102)
and 1.1% (1/88), respectively.
Sensitization to rPhl p 1 was detected in almost all
patients at all ages, and there was no significant increase
in the frequency of positivity to rPhl p 5 and to rPhl p 12
with the rise of the age. Monosensitization to rPhl p 1
decreased with the increase in the children’s age, although
without statistical significance (with Chi square test).
Dividing the patients in two groups according to
sensitization to “Species Specific” allergenic molecules
only (rPhl p 1, rPhl p 5; SS group with 135/207 patients)
and to “Species Specific” and Cross-Reactive allergenic
molecules (rPhl p 1, rPhl p 5, rPhl p 7 and rPhl p 12;
SSCR group with 72/207 patients), we evaluated the most
relevant pattern of respiratory and food sensitization of
our population of polysensitized children.
rPhl p 1 was found in 133/135 (98.5%) of SS group
patients and in 72/72 (100%) of the SSCR group, while
rPhl p 5 was found in 59% (80/135) of group SS patients
vs 82% (59/72) of the other group, with a significant
difference (χ2 =10.95; Yates’ χ2 = 9.95; p<0.01).
Children with IgE against “Species Specific” and
Cross-Reactive allergens were more frequently sensitized
to Parietaria judaica and Olea as aeroallergens and to
peanuts and tomato as foods in comparison to patients
with IgE against “Species Specific” allergenic molecules
only, with statistical significance (Table 3).
Par j 2 IgE levels were not evaluated in all patients
sensitized to Parietaria, but it was particularly interesting
to note that in patients without IgE against Cross-
Reactive allergenic molecules (SS group), the majority of
patients (with positive IgE for Parietaria) in whom Par j
2 IgE levels were studied (36/41 patients = 88%) were
highly sensitized to Parietaria; while only 50% of patients
(18/36) with IgE against Parietaria had also IgE against
Par j 2 in SSCR group (χ2=11.2, Yates’ χ2 = 9.6, p > 0.01).
It is also very remarkable that patients with IgE only
against “Species Specific” allergenic molecules of Pp did
not have IgE vs Bet v 2 (another profilin, tested on 44
patients of SS group), while IgE against Bet v 2 wereTable 3 Pattern of sensitization against to other aeroallergen
according to the positivity of IgE for only “Species Specific” a







Parietaria Judaica 82/135 patients (61%) 68/72 patie
Olea 105/135 patients (78%) 71/72 patie
Peanuts 30/135 patients (22%) 47/72 patie
Tomato 46/135 patients (34%) 58/72 patiefound in 83% (25 patients on 30, in which the profilin
was tested) of SSCR group, with statistical significance
(χ2 = 55.4, Yates’ χ2 = 51.7, p < 0.01).
There weren’t significant differences in clinical
symptoms such as asthma, rhinitis and conjunctivitis
according to different sensitization to Pp allergenic
molecules (SS group vs SSCR group). On the other
hand, patients who also had Cross-Reactive allergens
(SSCR group) were more often affected by anaphylaxis,
urticaria and angioedema caused by peanuts, tomato
and fruits (14/72 = 19.4% on SSCR vs 10/135 = 7% of SS
group), with statistical significance (χ2 = 6.64, p < 0.01;
Yates’ χ2 = 5.52, p < 0.05).
Discussion
Recombinant allergens can be produced as molecules
that exactly mimic the properties of the natural
allergens, or modified variants with advantageous prop-
erties such as reduced allergenic activity or increased
immunogenicity, or alternatively as hybrid molecules
resembling the epitopes of several different allergens to
include the relevant epitopes of complex allergen
sources [3]. Recombinant allergens can be used instead
of timothy grass pollen extracts, that exhibit a consider-
able heterogeneity regarding the presence of individual
allergens and hence yield a certain variability of the
results of the in vivo test. A single recombinant allergen
or a combination of a few major recombinant allergens
can substitute the crude extract for diagnostic purposes
in vitro and in vivo [17].
rPhl p 1 is considered by many authors the most im-
portant timothy grass pollen “Species Specific” allergen
[18-22], whereas other authors maintain that the rPhl p 5
is the most significant [23-27].
In a recent study, Casquete - Román et al. detected in
a pediatric population a total of 99.4% of the patients
classified as sensitized to grass pollen who yielded posi-
tive values (> 0.1 kUA/l) for the recombinant “Species
Specific” allergens (rPhl p 1 + rPhl p 5), while 46% of
them proved positive for the Cross-Reactive (rPhl p 7 +
rPhl p 12) allergens [1]. Rossi et al. found the following
frequency of sensitization in 77 patients (mean age 21.6
years): rPhl p1 = 93.5%; rPhl p 5 = 72.7%; rPhl p 7 = 7.8%;s (Parietaria and Olea) and foods (peanuts and tomato),
llergenic molecules (SS group) and “Species Specific” and





nts (94%) 26.7 25.1 < 0.01
nts (99%) 16.1 14.4 < 0.01
nts (65%) 8.9 8.1 < 0.01
nts (80%) 40.6 38.7 < 0.01
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(2010), Rossi detected in 33 patients (age range 9–62 years)
rPhl p 1 in 100% of patients, rPhl p 5 in 76%, rPhl p 7 in
3% and rPhl p 12 in 45% [28]. Mari found the following
data in sera of 749 grass-sensitized patients, selected on
a population of 4,606 unselected subjects, with an age
range of 2 to 70 years: rPhl p 1 = 83%, rPhl p 5 = 50%,
rPhl p 7 = 7%, rPhl p 12 = 15% and isolated reactivity
to rPhl p 1 in 6%, whereas it was negligible for the
remaining molecules [15].
Among the most important recombinant allergens we
measured rPhl p 1 and rPhl p 5, because they are
considered the major “Species Specific Allergens” in the
international literature [29-31] and rPhl p 12 and rPhl p 7,
the principal Cross-Reactive components. Our study has
shown the predominance in children with grass pollen
allergy of both of rPhl p 1 and rPhl p 5, found in 99%
and 67% of them, respectively.
The pan-allergen rPhl p 12 was detected in a notable
percentage of children (32%), while Valenta et al. [32]
reported that 20% of patients allergic to grass displayed
IgE reactivity to profilins.
The discrepancy between these frequencies of sensitization
is probably related to a geographical variation in aller-
gen exposure.
Sensitization only to “Species Specific” allergenic molecules
of Pp was observed very frequently, in more than half
of children (65%), while sensitization to “Species Spe-
cific” and Cross-Reactive allergenic molecules together
was found in a smaller percentage (35%). This may re-
flect the impact of large amounts of grass pollen in this
geographic area, as observed also by Rossi et al. [33].
rPhl p 1 was the only allergenic molecule of Pp detected
alone in a relevant percentage of patients (26%), while rPhl
p 5 was rarely found as the only sensitizing allergen (1%).
No patients were uniquely sensitized against rPhl p 7 and
rPhl p 12. Consequently, this study has shown that rPhl p 1
is the predominant grass pollen allergenic molecule,
sensitizing almost all patients both in association with
other rPhl and acting as a single allergen.
There was a significant correlation between serum IgE
against timothy grass pollen extract and Pp IgE levels.
Laffer et al. examined in sera of 183 patients allergic to
grass pollen from different populations (Europe, Japan, and
Canada) the in vitro IgE antibody-binding capacity to three
recombinant timothy allergens, rPhl p 1, rPhl p 2, rPhl p 5,
and birch profilin. More than 94% of patients could be
diagnosed with a combination of recombinant rPhl p 1,
rPhl p 2, rPhl p 5, and birch profilin, while the sera that did
not react with the recombinant allergens contained low
levels of timothy grass pollen-specific IgE antibodies. A
good correlation was observed between natural timothy-
serum specific IgE antibodies and the combination of
recombinant allergens in all 183 tested sera [34].The analysis of the IgE positivity for Pp allergenic
molecules according to timothy grass pollen-specific IgE
levels showed that rPhl p 1 IgE were detectable at any
level of grass pollen IgE (in 97% - 100% of patients), both
in children with a low grade of sensitization and in high
sensitized grass pollen patients, while monosensitization
to rPhl p 1 was very important in patients with lower grass
pollen IgE levels, disappearing with the increase in tim-
othy grass pollen-specific IgE antibodies (with statistical
significance). However, rPhl p 5 IgE positivity was raised
with the increase in grass pollen IgE level, with statis-
tically significant differences, and it became the same
as rPhl p 1 in patients with higher grass pollen IgE level
(≥ 100 kUA/l). Moreover, rPhl p 12 IgE positivity
increased with IgE against timothy grass pollen extract,
once again with significant differences.
Studying the pattern of sensitization to Pp allergens
according to the patients’ age, we have observed some
interesting age-related differences. Sensitization to rPhl 1
seems to appear early, even before the age of 5 years,
because it was found in 100% of our patients at this age.
rPhl p 5 sensitization, although detected in a smaller
percentage of children at the age < 5 years, was already
present at this age and its positivity increased with the
rise of the age (from 59% to 69% of children), although
without statistical significance.
Allergic disorders display a clinical evolution during
childhood and adolescence, related from an immuno-
logical viewpoint to the appearance of sensitizations to
food allergens during the first years of life, followed by
the onset of sensitization to inhalant allergens. The
number of allergen sensitizations increase from child-
hood, when mono- or oligo-sensitizations are common,
to adolescence, when polysensitization is more frequent
[35,36]. This concept may be at the basis of the different
frequency of sensitization to rPhl p1 and rPhl p 5 in
children with different ages. According to the majority
of studies, rPhl p 1 causes IgE reactivity in more than
90% of allergic subjects and exists in all grass species
[22], while the rate of detection of rPhl p 5 is 65%-85%
among populations of individuals allergic to grass pollen
from temperate regions [31]. The predominant role of
rPhl p 1 that dominates the immune response to grass
pollen extract may explain the detection of Phl p 1 IgE
at any level of grass pollen IgE and at all ages, detectable
also in very young children, in whom IgE against rPhl p 5
have poor relevance.
rPhl p 7 sensitization is insignificant in our population
and is completely absent in patients aged < 5 years.
The frequency of sensitization to rPhl p 12 increased
with the rise of the age (from 30% to 36% ones),
although without statistical significance.
Scala et al., using allergen-based microarray for
the detection of IgE-related sensitization to panels of
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ation for an IgE-based epidemiology. They observed that
seven thousand two hundred and forty-six patients
(44.16% of the total allergic cohort; 51% female) were
IgE reactive on ISAC to at least one of the timothy grass
pollen allergens as representative markers of other hom-
ologous grass allergens. Phl p 1 was the allergen most
frequently recognized. The mean age was 30.1 ± 16.5
years, significantly higher if compared with mite allergen
IgE-reactive subjects (p < 0.001), with the highest value
of IgE recognition reached between 15 and 25 years of
age. Phl p 2, 5, and 6 showed a similar behaviour of IgE
recognition, whereas the pan-allergens Phl p 7 and Phl p
12 showed a different pattern of IgE recognition, because
they did not generate any cluster with the molecules
belonging to their parental biological source. Pan-allergens
showed clustering trends with their homologous molecules
suggesting different pathways of primary immunological
sensitization [37].
Profilins (Phl p 12, Bet v 2) occur as highly Cross-
Reactive allergens in a variety of plants unrelated from a
botanical point of view and plant products. Patients pro-
ducing specific IgE antibodies are either sensitized or at
risk of developing allergic reactions to various plant
pollens and plant-derived foods [38].
In our pediatric population, children with IgE against
“Species Specific” and Cross-Reactive allergens were more
frequently sensitized to aeroallergens Parietaria judaica
and Olea and to foods peanuts and tomato compared to
patients with IgE against “Species Specific” allergenic
molecules only, with statistical significance. It is possible
that this difference can be related to a sensitization
for Cross-Reactive molecules. Indeed, among patients
sensitized to “Species Specific” and Cross-Reactive
molecules, only 50% were really allergic to Parietaria
(IgE against Parietaria + IgE against Par j 2), while
among patients only sensitized for “Species Specific”
Pp allergens, 88% were really sensitized to Parietaria.
It is also very remarkable that patients with IgE only
against “Species Specific” allergenic molecules of Pp
had not IgE vs Bet v 2, another profilin.
Considering possible correlations between clinical
symptoms and the pattern of sensitization to allergenic
molecules of Pp, we have observed that patients also
positive for Cross-Reactive allergens were more often
affected with anaphylaxis, urticaria and angioedema
caused by peanuts, tomato and fruits. Further studies
are needed to clarify the possible role of Cross-Reactive
allergens in the development of anaphylactic symptoms
due to plant-related foods.
The international literature largely reports that only a
limited number of recombinant timothy grass pollen
allergens account for a high percentage of IgE against
grass pollen extract; it is suggested the possible utility ofrecombinant allergens not only for in vitro diagnosis,
but probably also for specific immunotherapy [39]. With
the use of defined molecules instead of crude allergen
extract–based mixtures, it would be possible to know
more precisely the mechanisms underlying immunother-
apy and to develop new forms and perhaps prophylactic
immunotherapy strategies [3].
In agreement with this concept, a very recent study by
Tripodi et al. defined the compatibility of the profiles of
IgE sensitization to Pp with a mixture of recombinant al-
lergenic molecules of Pp previously proposed for specific
immunotherapy. Sera reacting against Pp were tested for
rPhl p 1, rPhl p 2, rPhl p 4, nPhl p 4, rPhl p 5b, rPhl p 6,
rPhl p 7, rPhl p 11, and Phl p 12 and the IgE individual
sensitization profiles were matched against an experimental
allergen-specific immunotherapy preparation containing
Phl p 1, Phl p 2, Phl p 5, and Phl p 6. The authors
concluded that molecularly designed immunotherapy
preparations tailored to patients’ needs should consider the
high heterogeneity of IgE sensitization profiles to Pp,
suggesting that trials are needed to test whether differ-
ent molecular sensitization profiles to grass pollen
underlie different clinical responses to the same im-
munotherapy preparation [40].
Our data show the predominant role of rPhl p 1 in
pediatric populations as the most relevant sensitizing
allergen detectable at all ages and at all levels of timothy
grass pollen-specific IgE antibodies, while the frequency of
rPhl p 5 rises with the increase in patients’ age and with
grass pollen IgE levels, supporting the possible use of both
allergens to create an immunotherapy tailored to the sin-
gle patient.
Conclusions
In conclusion, the assessment of sensitization to grass
pollen allergenic molecules could become an important tool
to achieve a better characterization of allergic sensitization
in grass pollen allergy in children, which may be differ-
ent in every patient, and also to give a more specific
and effective immunotherapy based on sensitization to
allergenic molecules.
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